Tags

Type your tag names separated by a space and hit enter

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Hum Pathol. 2008 Feb; 39(2):167-74.HP

Abstract

Previous studies have shown conflicting results on prognostic significance of basal-like breast tumors, but hormone receptor is a confusing factor in most of the prognostic evaluations. We aimed to characterize the prognostic features of basal-like tumors without the influence of hormone receptor status in a series of hormone receptor-negative breast tumors. Using tissue microarray and immunohistochemistry methods, according to the expression of HER2 and basal markers (CK5/6, CK14, EGFR), we categorized 713 consecutive hormone receptor-negative invasive breast cancers into 3 subtypes: HER2 (HER2+), basal-like (HER2-, any basal marker+), and null (HER2-, all basal markers-). The HER2 phenotype was subdivided into pure-HER2 (HER2+, all basal markers-) and basal-HER2 (HER2+, any basal marker+) subgroups. Expression of p53, p63, vimentin, and BRCA1 was assessed immunochemically. Basal-like tumors showed significantly higher grade, more frequent recurrence, and higher expression of vimentin and p63 than HER2 and null phenotypes. Basal-HER2 phenotype had significantly younger mean age and expressed a higher level of p53 and vimentin like basal-like and/or HER2 phenotypes. However, unlike all the other hormone receptor-negative phenotypes, they highly expressed BRCA1. No significant difference was found in 5-year survival among basal-like and the other hormone receptor-negative phenotypes, except for basal-HER2, which showed poorer 5-year overall survival than basal-like tumors. In conclusion, although basal-like breast tumors have distinct clinicopathologic and immunohistochemical features, they have similar 5-year survival compared with the other hormone receptor-negative tumors including HER2 and null phenotypes. However, there exists a small group of hormone receptor-negative tumors expressing HER2 and basal markers simultaneously. This small group of tumors showed significantly poorer 5-year overall survival than basal-like breast tumors and might require different treatment strategy.

Authors+Show Affiliations

Department of Pathology, Nanjing Medical University, Nanjing 210029, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18045647

Citation

Liu, Hui, et al. "Basal-HER2 Phenotype Shows Poorer Survival Than Basal-like Phenotype in Hormone Receptor-negative Invasive Breast Cancers." Human Pathology, vol. 39, no. 2, 2008, pp. 167-74.
Liu H, Fan Q, Zhang Z, et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008;39(2):167-74.
Liu, H., Fan, Q., Zhang, Z., Li, X., Yu, H., & Meng, F. (2008). Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Human Pathology, 39(2), 167-74.
Liu H, et al. Basal-HER2 Phenotype Shows Poorer Survival Than Basal-like Phenotype in Hormone Receptor-negative Invasive Breast Cancers. Hum Pathol. 2008;39(2):167-74. PubMed PMID: 18045647.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. AU - Liu,Hui, AU - Fan,Qinhe, AU - Zhang,Zhihong, AU - Li,Xiao, AU - Yu,Huiping, AU - Meng,Fanqing, Y1 - 2007/11/28/ PY - 2007/05/15/received PY - 2007/06/22/revised PY - 2007/06/29/accepted PY - 2007/11/30/pubmed PY - 2008/2/20/medline PY - 2007/11/30/entrez SP - 167 EP - 74 JF - Human pathology JO - Hum Pathol VL - 39 IS - 2 N2 - Previous studies have shown conflicting results on prognostic significance of basal-like breast tumors, but hormone receptor is a confusing factor in most of the prognostic evaluations. We aimed to characterize the prognostic features of basal-like tumors without the influence of hormone receptor status in a series of hormone receptor-negative breast tumors. Using tissue microarray and immunohistochemistry methods, according to the expression of HER2 and basal markers (CK5/6, CK14, EGFR), we categorized 713 consecutive hormone receptor-negative invasive breast cancers into 3 subtypes: HER2 (HER2+), basal-like (HER2-, any basal marker+), and null (HER2-, all basal markers-). The HER2 phenotype was subdivided into pure-HER2 (HER2+, all basal markers-) and basal-HER2 (HER2+, any basal marker+) subgroups. Expression of p53, p63, vimentin, and BRCA1 was assessed immunochemically. Basal-like tumors showed significantly higher grade, more frequent recurrence, and higher expression of vimentin and p63 than HER2 and null phenotypes. Basal-HER2 phenotype had significantly younger mean age and expressed a higher level of p53 and vimentin like basal-like and/or HER2 phenotypes. However, unlike all the other hormone receptor-negative phenotypes, they highly expressed BRCA1. No significant difference was found in 5-year survival among basal-like and the other hormone receptor-negative phenotypes, except for basal-HER2, which showed poorer 5-year overall survival than basal-like tumors. In conclusion, although basal-like breast tumors have distinct clinicopathologic and immunohistochemical features, they have similar 5-year survival compared with the other hormone receptor-negative tumors including HER2 and null phenotypes. However, there exists a small group of hormone receptor-negative tumors expressing HER2 and basal markers simultaneously. This small group of tumors showed significantly poorer 5-year overall survival than basal-like breast tumors and might require different treatment strategy. SN - 0046-8177 UR - https://www.unboundmedicine.com/medline/citation/18045647/Basal_HER2_phenotype_shows_poorer_survival_than_basal_like_phenotype_in_hormone_receptor_negative_invasive_breast_cancers_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0046-8177(07)00354-1 DB - PRIME DP - Unbound Medicine ER -